Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. (2014)
Attributed to:
MRC Centre for Transplantation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00277-013-1863-5
PubMed Identifier: 24018623
Publication URI: http://europepmc.org/abstract/MED/24018623
Type: Journal Article/Review
Volume: 93
Parent Publication: Annals of hematology
Issue: 1
ISSN: 0939-5555